---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-002406"
form_type: "8-K"
ticker: "HEPA"
cik: "0001583771"
company_name: "Hepion Pharmaceuticals, Inc."
filed_at: "2022-01-10T23:59:59+00:00"
generated_at: "2026-06-27T19:25:27.766085+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Hepion provides pipeline update: Rencofilstat Phase 2a NASH trial positive; Phase 2b and HCC trials underway

## Summary
- Phase 2a NASH trial (AMBITION) met safety endpoints; showed ALT and Pro-C3 reductions over 28 days.
- Cash $98.7M as of Sept 30, 2021; 76.2M shares outstanding.
- Phase 2b NASH trial (ASCEND-NASH) to randomize 336 subjects across 75, 150, 225 mg doses for 12 months.
- Phase 2a HCC trial (HEPA-RENCOFILSTAT-209) launched with Simon 2-stage design; primary endpoint disease control rate.
- AI-POWR platform predicts responders; transcriptomics misclassification error <5% in Phase 2a analysis.

## SEC filing metadata
- accession: 0001104659-22-002406
- form_type: 8-K
- ticker: HEPA
- cik: 0001583771
- company_name: Hepion Pharmaceuticals, Inc.
- filed_at: 2022-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583771/000110465922002406/0001104659-22-002406-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583771/000110465922002406/tm222379d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-002406
- JSON: https://secwatch.observer/filing/0001104659-22-002406.json
- Plain text: https://secwatch.observer/filing/0001104659-22-002406.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.